168638 research outputs found
Sort by
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13\u201317 Years \u2014 United States, 2017: Supplementary Figure 1. HPV Vaccination Initiation ( 651 Dose)and HPV Up-to-date (UTD) Status Estimates Among Adolescents by Age 13 Years, by Birth Cohort \u2014NIS-Teen, United States, 2016\u20132017 ; for National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13\u201317 Years \u2014 United States, 2017
No full textEmerg Infect Dis
No full textTo investigate the genetic background for the emergence of macrolide resistance, we characterized the genetic features of Mycoplasma pneumoniae using multilocus sequence typing. Of the 146 M. pneumoniae strains collected during the 5 consecutive outbreaks of M. pneumoniae pneumonia during 2000-2016 in South Korea, macrolide resistance increased from 0% in the first outbreak to 84.4% in the fifth. Among the 8 sequence types (STs) identified, ST3 (74.7%) was the most prevalent, followed by ST14 (15.1%). Macrolide-susceptible strains comprised 8 different STs, and all macrolide-resistant strains were ST3 (98.3%) except 1 with ST14. The proportion of macrolide-resistant strains in ST3 remained 2.2% (1/46) until the 2006-2007 outbreak and then markedly increased to 82.6% (19/23) during the 2010-2012 outbreak and 95.0% (38/40) during the 2014-2016 outbreak. The findings demonstrated that clonal expansion of ST3 M. pneumoniae was associated with the increase in macrolide resistance in South Korea
Arthropod-Borne Virus Information Exchange: Number Two: September 1960
Get PDFIntroductory Notes from the Sub-committee on Information Exchange -- Reports from \u2026. [including: REPORT FROM DR. E. RUSSELL ALEXANDER, CHIEF, SURVEILLANCE SECTION, U.S.P.H.S. COMMUNICABLE DISEASE CENTER, ATLANTA, GEORGIA;REPORT FROM DR. ARCHIE D. HESS, CHIEF, ENCEPHALITIS SECTION, TECHNOLOGY BRANCH, U.S.P.H.S., COMMUNICABLE DISEASE CENTER, GREELEY, COLORADO] -- Notes from University of Minnesota Medical School, Minneapolis -- Notes from Department of Veterinary Science, University of Wisconsin -- List of Annual and Other Reports Received-- Current mailing list
Contact Lens Health Week : August 20-24, 2018
No full textContact Lens Health Week - #OnePairTakeCarewww.cdc.gov/contactlenses201
Ann Epidemiol
Get PDFPurpose:Current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data.Methods:Data on prostate cancer cases came from the 2004\u20142014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC).Results:We identified 2,137,054 incident prostate cancers diagnosed during 2004\u20142014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004\u20142010 (APC = 121.2) and increased during 2010\u20142014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65\u201474 and older than or equal to 85 years, in men with white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5).Conclusions:Using data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010\u20142014 among men in certain ages, in white, and with non-Hispanic ethnicity.CC999999/Intramural CDC HHS/United States2018-08-07T00:00:00Z29678312PMC6080305vault:3065
Med Mycol
Get PDFIn Arizona during 1997-2013, coccidioidomycosis increased from 21 to 90 cases/100,000 population, but coccidioidomycosis-associated deaths remained stable at 3-6 deaths/million population. We used the capture-recapture method by using death certificates and hospital discharge data to more fully estimate the total number of coccidioidomycosis-attributable deaths and compared this with published estimates. Death certificates were included if any cause of death included coccidioidomycosis; hospital discharge data deaths were included if any discharge diagnosis included coccidioidomycosis and laboratory confirmation. Among deaths during 2008-2013, we identified 529 coccidioidomycosis-attributable deaths from death certificates and 560 from hospital discharge data, with 251 deaths identified in both databases. Capture-recapture estimated 1,178 total coccidioidomycosis-attributable deaths, compared with 164 deaths (underlying cause of death) or 529 deaths (any cause of death) on death certificates. Coccidioidomycosis-attributable deaths are underreported from two- to sevenfold on Arizona death certificates, demonstrating an education need for death certifiers to document coccidioidomycosis mortality.CC999999/Intramural CDC HHSUnited States
Do your part for vaccine safety - report to VAERS
Get PDFIf one of your patients becomes ill after being vaccinated, promptly report it to the Vaccine Adverse Event Reporting System (VAERS), even if you are not sure that the vaccine caused the illness.As a healthcare provider, you can help to ensure the safety of vaccines given to patients in the United States by reporting adverse events to VAERS.VAERS is a national vaccine safety surveillance program, co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). VAERS is a post-licensure surveillance program that collects information about adverse events (possible side effects) that occur after the administration of vaccines licensed for use in the United States.CS207429Publication date from document properties.vaers-poster2-17x22-bw.pdf201
Maternal vaccination : resources for healthcare professionals
Get PDFVaccines help keep your pregnant patients and their growing families healthy.Last Updated September, 2016CS HCVG15-MAT-104immunizations-preg-chart.pdf201